[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-serous-chorioretinopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-serous-chorioretinopathy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,66,94,124,145,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100556609","the-study-of-the-association-between-the-gut-microbiota-and-central-serous-chorioretinopathy-100556609",false,"NCT06527326","the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy","Inclusion Criteria:\n\n* Age 18 to 60 years\n* Diagnosis of acute central serous chorioretinopathy (CSC) (affected eye: ① FFA and ICGA showing typical CSC manifestations, ② presence of subretinal fluid (SRF) at the macular fovea, ③ disease duration ≤ 6 months)\n* Best Corrected Visual Acuity (BCVA): 53 to 86 letters\n* Other: No significant systemic diseases, signed informed consent, and able to commit to follow-up\n\nExclusion Criteria:\n\n* Presence of significant systemic diseases\n* BCVA of 20\u002F200 or worse\n* Presence of choroidal or retinal atrophy in the macular fovea of the affected eye\n* Presence of choroidal neovascularization (CNV), age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), diabetic retinopathy (DR), choroidal hemangioma, pigment epithelial detachment (PED), etc., in the affected eye\n* High myopia in the affected eye",true,"ALL",{"count":18,"type":19},400,"ESTIMATED","INTERVENTIONAL",[22],"NA","To investigate the potential association between gut microbiota and central serous chorioretinopathy (CSC), clinical observations have indicated that patients with CSC frequently present with chronic gastrointestinal symptoms. This observation has led to the hypothesis that CSC may be associated with gut dysbiosis.\n\nThe genus Bifidobacterium is widely recognized as a beneficial component of the gut microbiota, and multiple well-established Bifidobacterium supplements are commercially available. To explore this potential association, fecal samples will be collected from both CSC patients and healthy controls. Whole-metagenome shotgun sequencing will be performed to compare gut microbial compositions between the two groups and to determine whether significant differences exist.\n\nIn addition, CSC patients will be randomly assigned to two groups. One group will receive Bifidobacterium supplementation for a minimum of one month, while the other group will receive a placebo. Clinical outcomes will then be evaluated to assess whether Bifidobacterium supplementation is associated with faster recovery and reduced relapse rates compared with placebo.",[25],"Central Serous Chorioretinopathy",[27,28,29],"central serous chorioretinopathy","Bifidobacterium genus","the gut dysbiosis","RECRUITING","2026-05-24",{"date":33,"type":34},"2026-05-27","ACTUAL",{"date":33,"type":19},{"date":37,"type":19},"2028-07-01",{"name":39,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100542710","central-serous-chorioretinopathy-and-micropulse-laser-treatment-100542710","NCT06346405","Central Serous Chorioretinopathy and Micropulse Laser Treatment","Central Serous Chorioretinopathy and Micropulse Laser Treatment: Evaluation of Morphological and Functional Recovery","LEVEO","Inclusion Criteria:\n\n* Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.\n* Foveal serous retinal detachment for at least 6 months.\n* Minimum age of 18 years old at the screening time\n* Reading and comprehension skills of informed consent\n\nExclusion Criteria:\n\n* Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone\n* No diffuse retinal epitheliopathy\n* Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization\n* Not controlled glaucoma with eyedrops, or advanced glaucoma\n* Myopia or hypermetropia greater than 6 diopters\n* Opacities of dioptric media\n* Low quality of optical coherence tomography (OCT) and OCT-Angiography scans\n* Low quality images of Fluorescein angiography and indocyanine green angiography\n* No written consensus signed.","18 Years","70 Years",{"count":53,"type":19},36,"OBSERVATIONAL","To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and\u002For Eplerenone",[25],"2025-09-17",{"date":59,"type":34},"2025-09-23",{"date":61,"type":34},"2023-05-31",{"date":63,"type":19},"2027-05-31",{"name":65,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":20,"phases":75,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100578319","phase-2-evaluating-efficacy-and-safety-of-oral-melatonin-in-acute-central-serous-chorioretinopathy-100578319","NCT06809751","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy (CSCR): a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks\n2. Patients with minimum age of 18 years old\n3. Consent to participate in the study\n\nExclusion Criteria:\n\n1. A history of vitrectomy\n2. A history of laser surgery in the eye being studied in the past 3 months\n3. A history of anti-VEGF injection in the eye being studied in the past 3 months\n4. History of patient suspicious for choroidal neovascularization (CNV)\n5. Pregnant or nursing patients\n6. Patients with significantly compromised visual acuity in the eye being studied due to concomitant ocular condition\n7. Patients participating in any other investigational drug study\n8. Inability to obtain OCT photographs",{"count":74,"type":19},48,[76,77],"PHASE2","PHASE3","The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:\n\n1. How does melatonin affect central macula thickness in CSCR?\n2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.\n\nParticipants will:\n\n1. Take melatonin or placebo twice a day for one month\n2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests\n3. Keep a diary of their symptoms",[25,80,81,82,83],"Melatonin","Ocular Diseases","Visual Acuity","Macula Abnormality","NOT_YET_RECRUITING","2025-01-30",{"date":87,"type":34},"2025-02-05",{"date":89,"type":19},"2025-02-01",{"date":91,"type":19},"2025-06-01",{"name":93,"class":40},"Mohsen Pourazizi",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":102,"targetDuration":4,"studyType":20,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100483096","subthreshold-nanosecond-laser-for-non-resolving-central-serous-chorioretinopathy-100483096","NCT05570591","Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy","Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy: A Double-masked Sham-controlled Randomised Trial","NANO-C","Inclusion Criteria:\n\n1. Age 18-70 years\n2. Both males and females\n3. Individuals with non-resolving CSCR as defined by presence of any SRF on OCT for \\> 3 months from date of diagnosis to randomisation visit\n4. BCVA of 35 to 80 letters (Snellen equivalent of 6\u002F6 to 6\u002F60) in the study eye\n5. Ability, willingness and sufficient cognitive awareness to consent to the trial, received randomised SNL treatment or sham procedure, and complete all visits as per the study schedule\n\nExclusion Criteria:\n\n1. A need for extraneous, continuous steroids to control any disease, including both systemic steroids (e.g., for systemic autoimmune conditions) and ocular steroids (e.g., for uveitis), or ongoing anabolic steroid use\n2. Any systemic disease that leads to elevated endogenous steroid levels including raised 24h urinary cortisol level \\> 100 ug\u002F24h consistent with Cushing's syndrome\n3. Any ocular disease in the study eye, other than CSCR, which in the opinion of the investigator may significantly compromise assessment of the retina, or which would compromise the ability to assess any effect following SNL treatment including, but not limited to:\n\n   * Age related macular degeneration\n   * Any evidence of a neovascular membrane in the macular (either exudative or non-exudative)\n   * Diabetic retinopathy (unless limited to fewer than 10 microaneurysms and\u002For small retinal haemorrhages, without retinal thickening on OCT)\n   * Macular pathology or pigmentary abnormalities including but not limited to: pattern dystrophy, myopic maculopathy, angioid streaks, resumed ocular histoplasmosis syndrome, visually-significant epiretinal membranes, macular hole or pseudohole\n   * Optic nerve pathology, including optic atrophy, history of optic neuropathy\n   * Myopic crescent wider than 50% of the longest diameter of the optic disc, or closer than 1500 µm to the fovea\n   * Retinal vascular diseases including branch or central vein or artery occlusion\n   * Choroidal nevus within 2 DD of the fovea associated with depigmentation or overlying drusen, if these drusen are used to determine eligibility\n   * Active uveitis or ocular inflammation\n   * Corneal pathology precluding visualization of fundus or increasing the risk of using a contact lens, such as corneal dystrophy, recurrent corneal erosion syndrome or sensitivity to the application of a contact lens\n4. History or presence of uncontrolled glaucoma or raised intraocular pressure which would preclude safe dilation of the pupil to allow adequate assessment and application of SNL treatment\n5. History of prior laser surgery to the retina including subthreshold laser (focal retinopexy for a peripheral retinal tear performed more than 90 days prior to the entry into the study is permitted)\n6. Significant cataract or other ocular media which, in the opinion of the investigator, significantly limits the visual acuity or view of the retina\n7. Cataract surgery within three months preceding baseline, or a history of post-operative complications within the last 12 months preceding baseline in the study eye (uveitis, cyclitis, etc.)\n8. Previous retinal or ocular surgery, the effects of which may now or in the future complicate assessment of CSCR (routine cataract surgery more than 3 months prior is permitted)\n9. Known hypersensitivity to fluorescein\n10. Use of any systemic or ocular medication known to be toxic to the retina, excluding tamoxifen unless there is evidence of toxicity\n11. Pregnant or lactating women\n12. Current participation in any other investigational ophthalmological clinical trial\n13. Other health-related reasons which make an individual inappropriate for participation in this study based on the investigator's medical judgment",{"count":103,"type":19},60,[22],"This is a prospective, multicentre, sham-controlled, participant- and assessor-masked superiority trial with two parallel treatment arms which aims to investigate the safety and efficacy of subthreshold nanosecond laser (SNL) in a series of adults with sub-retinal fluid secondary to non-resolving central serous chorioretinopathy (CSCR) by visual and anatomical outcomes.\n\nThe study population will be individuals with adults (aged 18-70 years inclusive) with non-resolving CSCR (defined as CSCR present for a duration of more than 3 months presenting with either focal or diffuse leakage) who meet all eligibility criteria.\n\n60 subjects total will be enrolled into the study - 40 randomized to receive SNL treatment and 20 to receive sham treatment as per a 2:1 randomization schedule and stratified by type of CSCR (focal vs diffuse).\n\nThe study has a 24-week study period with five scheduled visits: screening, randomisation (first treatment), 6-week follow up (with second treatment where eligible), 12-week follow-up , 18-week follow-up, and 24-week follow-up.\n\nThe primary outcome is the proportion of laser-treated study eyes that show resolution of sub-retinal fluid (SRF) as observed on optical coherence tomography (OCT) compared to sham-treated study eyes at 24 weeks.\n\nThe safety endpoint will be proportion of laser-treated eyes that lose ≥10 letters of of vision (measured on a standard vision chart) compared to sham-treated study eyes and fellow eyes over 24 weeks.",[25],[108,109,110,111,25,112],"Subthreshold nanosecond laser","Laser","2RT","CSR","Chorioretinopathy","2024-06-20",{"date":115,"type":34},"2024-06-24",{"date":117,"type":34},"2022-10-18",{"date":119,"type":19},"2024-12-31",{"name":121,"class":122},"Nova Eye Medical Pty Ltd.","INDUSTRY",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":131,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100552088","combination-of-micropulse-laser-with-or-without-photodynamic-therapy-for-chronic-central-serous-chorioretinopathy-100552088","NCT06468540","Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","Comparative Study on the Efficacy of the Combination of Micropulse Laser With or Without Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinal Disease","Inclusion Criteria:\n\n* Age \\>18 years old.\n* The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.\n* Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.\n* Patients had follow-up data before and after treatment for 1 month and at least 6 months.\n\nExclusion Criteria:\n\n* Patients with other fundus diseases or refractive interstitial opacity.\n* During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.\n* Various reasons led to incomplete patient data.",{"count":103,"type":19},"In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.",[25,134,135],"Micropulse Laser","Photodynamic Therapy","2024-06-15",{"date":138,"type":34},"2024-06-21",{"date":136,"type":19},{"date":141,"type":19},"2025-12-15",{"name":143,"class":144},"Beijing Hospital","OTHER_GOV",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":151,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":41},"100484586","choroidal-blood-flow-in-acute-and-chronic-central-serous-chorioretinopathy-100484586","NCT05589974","Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy","Inclusion Criteria:-\n\n* Able to sign informed consent\n* Possible to obtain fundus imaging\n* Acute CSC ˂4 months of duration in one eye, defined as:\n\n  1. Subfoveal presence of SRF on OCT\n  2. Present attack is 1st -3rd attack of CSC\n\n  b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT\n* Chronic CSC ≥4 months of duration in one eye, defined as:\n\n  1. Subfoveal presence of SRF on OCT\n  2. Subjective visual loss\u002Fsymptoms\n  3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT\n  4. Patient history and examination consistent with chronic CSC\n\nExclusion Criteria:\n\n* History of retinal disease other than CSC (e.g. retinal detachment)\n* Contraindications for FA, ICGA or PDT (only for chronic CSC)",{"count":152,"type":19},50,"Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.",[25],"2024-03-14",{"date":157,"type":34},"2024-03-18",{"date":159,"type":34},"2022-10-01",{"date":161,"type":19},"2026-07-31",{"name":163,"class":144},"Helse Stavanger HF",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100219996","oct-in-rare-chorioretinal-diseases-100219996","NCT02141308","OCT in Rare Chorioretinal Diseases","Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases","Subject-Level Criteria:\n\nInclusion a. Diagnosis of retinal or choroidal disease\n\nExclusion\n\n1. Inability to give informed consent.\n2. Inability to complete study tests within a 30 day period\n3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant.\n4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).\n5. Blood pressure \\> 180\u002F110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180\u002F110 by anti-hypertensive treatment, subject can become eligible.\n6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography.\n\nStudy-Eye Criteria:\n\nInclusion\n\na. Diagnosis of retinal or choroidal disease\n\nExclusion\n\n1. Inability to maintain stable fixation for OCT imaging.\n2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract)\n3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20\u002F40 or worse if the eye was otherwise normal).\n4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.","7 Years","100 Years",{"count":174,"type":19},150,"This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels.\n\nThe purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.",[177,178,179,180,25],"Retinal Artery Occlusions","Polypoidal Choroidal Vasculopathy","Retinal Arterial Macroaneurysm","Juxtafoveal Telangiecasia",[182,183,184],"Retina","Optical coherence tomography","Imaging","2024-02-08",{"date":187,"type":34},"2024-02-12",{"date":189,"type":34},"2014-05",{"date":191,"type":19},"2026-12",{"name":193,"class":40},"Oregon Health and Science University"]